Instrument Inactif

Autres langues Freeline Therapeutics Holdings plc

Actions

FRLN

US35655L2060

Recherche biotechnologique et médicale

Autres langues

22/08	Spur Therapeutics Limited Announces Termination of Michael John Parini from Director Appointment, Effective July 31, 2026
19/08	Spur Therapeutics Limited Announces Appointment of Henning Stennicke to Director, Effective August 17, 2026
14/07	Spur Therapeutics Announces CEO Michael Parini Will Transition to Chair of the Board of Directors, Effective July 31, 2026
14/07	Spur Therapeutics Announces Executive Transitions
07/07	Spur Therapeutics Doses First Patient In GALILEO-3 Pivotal Clinical Trial Of FLT201 For Gaucher Disease Type 1
04/05	Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of Flt201 in Adults with Gaucher Disease Type 1
04/02	Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease At 22Nd Annual Worthldsymposium
09/10/25	Spur Therapeutics Limited Auditor Raises 'Going Concern' Doubt
09/10/25	Spur Therapeutics Limited Reports Earnings Results for the Full Year Ended December 31, 2024
07/10/25	Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease At ESGCT 32nd Annual Congress
01/10/25	Spur Therapeutics to Present New Clinical Data on Its Gene Therapy Candidate in Gaucher Disease at Upcoming ESGCT Annual Congress
06/06/25	Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson's Disease at 2025 GBA1 Meeting
27/05/25	Spur Therapeutics Publishes Preclinical Proof-Of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease
15/05/25	Spur Therapeutics Presents Positive New Clinical and Preclinical Data on Its Gene Therapy Programs at ASGCT 28th Annual Meeting
04/02/25	Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium
31/10/24	Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, Its Gene Therapy Candidate in Adrenomyeloneuropathy
23/10/24	Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201
08/07/24	Spur Therapeutics Completes Enrollment in Phase 1/2 Galileo-1 Trial of Flt201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial
17/06/24	Freeline Therapeutics Announces New Name and Brand
17/06/24	Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP.
22/05/24	Spur Therapeutics Limited Auditor Raises 'Going Concern' Doubt
22/05/24	Freeline Therapeutics Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023
09/05/24	Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting
24/04/24	Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
20/02/24	Syncona’s Takeover of Freeline Therapeutics Becomes Effective